The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on Wednesday. That sort of risk event has the power to rock financial markets. Investors looking for stocks to buy should look outside of the crowded names out there. Yes, there are opportunities outside of the Mag 7. One way to uncover these opportunities is by leaning on the Zacks Rank. Stocks with favorable Zacks Ranks have strong earnings trends which could spell profits in the future. ...

MIAMI, Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims. PreCheck Health Services is excited to introduce this test under the name SolidTumorCheck+, marking the beginning of a new phase in precision oncology and pa ...

SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.Today's judgment confirms Illumina's longstanding view that the European Commission exceeded its authority by asserting jurisdiction over this merger. The basis for the 432 million euro fine has now been removed a ...

Illumina, Inc. (ILMN) has secured the FDA’s approval for its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and first two companion diagnostic (CDx) indications. The test analyses more than 500 genes to profile a patient's solid tumor, improving the chances of identifying an immuno-oncology or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.The latest development marks a long-awaited milestone for the company’s oncology customers and c ...

"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...

Investors in Illumina, Inc. (ILMN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $75 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean ...

da-kukIntroduction Illumina (NASDAQ:ILMN) has finally rid itself of GRAIL. My last look at the stock followed its 2023 financial report, wherein revenues and gross margins dropped and SG&A expenses climbed. The company also projected "approximately flat" revenues in 2024. This was in the context of a valuation that was rich. My recommendation was "sell," noting that the company's "premium valuation is not justified by its current performance or future prospects." Illumina stock is -1.68% since this upda ...

blackred Illumina, Inc. (NASDAQ:ILMN), the life sciences and tool company, is a company I’ve had my eye on for quite some time. I’ve never invested in this company before, and now might be the time to start a position. In this article, I will outline why I think it looks bullish. I will use technical analysis tools such as price action, volume, momentum, and relative strength to explain my reasoning. Chart 1 – ILMN Weekly with 30- Week Moving Average, Momentum, Volume, and Relative Strength StockCharts. ...

Illumina, Inc. (NASDAQ:ILMN) 2024 Strategy Update Summary Company Overview - **Company**: Illumina, Inc. - **Industry**: Genomics and Biotechnology - **Event Date**: August 13, 2024 - **Participants**: Jacob Thaysen (CEO), Steve Barnard (CTO), Ankur Dhingra (CFO) Key Points Vision and Growth Strategy - Illumina aims to redefine genomics through next-generation sequencing (NGS) and has a mission to improve patient outcomes by reducing diagnosis wait times from weeks to days [3][4] - The company is shifting focus from cost per gigabase to total cost of workflow, emphasizing high-quality biological insights [5][6] Market Opportunity - The total addressable market for Illumina is over $125 billion, with only $10 billion currently served by NGS [8] - The clinical market is expected to grow significantly, particularly in liquid biopsy, which is projected to reach $800 million with a 34% CAGR [9][10] Product Innovations - The NovaSeq X Series is a key enabler for expanding applications in genomics, with nearly half of high-throughput data sequenced on the X Plus by the end of Q2 2024 [11] - Illumina is focusing on multiomics, integrating various biological insights, and enhancing customer workflows through innovative technologies [12][18] Financial Outlook - Illumina targets high single-digit revenue growth by 2027, driven by core sequencing, multiomics, and expanded services [49][63] - The company has seen GB output growth of over 25% annually, with recent quarters showing growth rates of 35% to 40% [50] Margin Expansion - Illumina aims to expand operating margins by 500 basis points through 2027, with a goal of achieving a top quartile margin performance among peers [59] - The company has implemented cost-saving measures, including a 10% reduction in workforce and optimizing real estate [48][60] Customer-Centric Approach - Illumina is committed to understanding and addressing the diverse needs of its customer base, focusing on partnerships rather than vendor relationships [58] - The company is enhancing its R&D pipeline to ensure alignment with customer needs and market demands [57] Future Innovations - Upcoming products include a 5-base genome technology that provides both variant and epigenetic information in a single workflow, and a comprehensive genome that simplifies library preparation [35][36] - Illumina is also advancing its proteomics capabilities and integrating multiomic data analysis through platforms like Partek [39][40] Conclusion - Illumina is positioned for significant growth and innovation in the genomics space, with a clear strategy to enhance customer experience, expand market reach, and improve financial performance [64][63]

-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics-- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost-- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027-- Illumina and the Broad Institute of MIT and Harvard announce new resear ...